Individualized care for patients with cancer - A work in progress

被引：38

作者：

Bast, RC

Hortobagyi, GN

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 27期

关键词：

D O I：

10.1056/NEJMe048300

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2865 / 2867

页数：3

共 14 条

[1]

Abe O, 1998, LANCET, V352, P930

[2]

ALBAIN KS, 2002, PROG P AM SOC CLIN O, V21, pZ37

[3] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[4]

Baum M, 2002, LANCET, V359, P2131

[5]

BAUM M, 2002, LANCET, V360, P1520

[6] Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [J].

Chang, JC ;

Wooten, EC ;

Tsimelzon, A ;

Hilsenbeck, SG ;

Gutierrez, MC ;

Elledge, R ;

Mohsin, S ;

Osborne, CK ;

Chamness, GC ;

Allred, DC ;

O'Connell, P .

LANCET, 2003, 362 (9381) :362-369

[7]

Clarke M, 1998, LANCET, V351, P1451

[8] Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis [J].

Cole, BF ;

Gelber, RD ;

Gelber, S ;

Coates, AS ;

Goldhirsch, A .

LANCET, 2001, 358 (9278) :277-286

[9]

Esteva FJ, 2003, BREAST CANCER RES TR, V82, pS11

[10]

Gianni L, 2004, J CLIN ONCOL, V22, p3S

← 1 2 →